EWA
BCYC

EverSource Wealth Advisors’s Bicycle Therapeutics BCYC Stock Holding History

EverSource Wealth Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6
Closed -$42 – 4397
2025
Q4 		$42 Hold
6
– – ﹤0.01% 4182
2025
Q3 		$46 Buy
+6
New +$45 ﹤0.01% 4257
2025
Q2 		– Sell
-13
Closed -$110 – 4261
2025
Q1 		$110 Sell
13
-11
-46% -$130 ﹤0.01% 3815
2024
Q4 		$336 Buy
24
+4
+20% +$86 ﹤0.01% 3313
2024
Q3 		$453 Buy
+20
New +$461 ﹤0.01% 2893

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EverSource Wealth Advisors's BCYC Position: Q1 2026 in Review

EverSource Wealth Advisors sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 6 shares — an estimated $42 sold.

EverSource Wealth Advisors first reported a position in BCYC in Q3 2024 and held it in 5 quarters. The position peaked at $453 in Q3 2024. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • EverSource Wealth Advisors reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
  • EverSource Wealth Advisors sold 6 Bicycle Therapeutics shares in Q1 2026, an estimated $42.
  • EverSource Wealth Advisors first reported a position in Bicycle Therapeutics in Q3 2024 and held it in 5 quarters.
  • EverSource Wealth Advisors's Bicycle Therapeutics position peaked at $453 in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.